GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
122.64
+4.83 (4.10%)
Oct 19, 2026, 1:40 PM EDT - Market open
GRAIL Revenue
GRAIL had revenue of $44.69M in the quarter ending June 30, 2026, with 25.72% growth. This brings the company's total for the last twelve months to $165.26M, up 23.07% year-over-year. In the year 2025, GRAIL had annual revenue of $147.17M with 17.18% growth. That makes GRAIL the 18,859th largest company in the world by revenue and 3,004th in the United States.
Revenue (ttm)
$165.26M
Revenue Growth
+23.07%
P/S Ratio
33.32
Revenue / Employee
$181,608
Employees
910
Market Cap
5.48B
Revenue by Geography
- United States 137.09M 93.2%
- International 10.08M 6.8%
Fiscal year ended Dec 31, 2025 See the full GRAIL breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 147.17M | 21.58M | 17.18% |
| Dec 31, 2024 | 125.60M | 32.49M | 34.90% |
| Dec 31, 2023 | 93.11M | 37.56M | 67.61% |
| Jan 1, 2023 | 55.55M | 40.94M | 280.17% |
| Jan 2, 2022 | 14.61M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ICON Public Limited Company | 8.29B |
| Charles River Laboratories International | 4.00B |
| RadNet | 2.27B |
| Qiagen | 2.10B |
| Sotera Health Company | 1.22B |
| NeoGenomics | 766.30M |
| Veracyte | 561.90M |
| CareDx | 458.09M |
GRAL News
- 6 days ago - Grail price target raised to $180 from $88 at TD Cowen - TheFly
- 7 days ago - Grail price target raised to $120 from $60 at Morgan Stanley - TheFly
- 13 days ago - GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026 - PRNewsWire
- 17 days ago - Grail price target raised to $175 from $105 at UBS - TheFly
- 17 days ago - Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms - Reuters
- 18 days ago - Grail price target raised to $155 from $75 at Guggenheim - TheFly
- 21 days ago - Grail price target raised to $150 from $80 at Canaccord - TheFly
- 24 days ago - Grail price target raised to $100 from $65 at Mizuho - TheFly